Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

Presentation TCT 2025

TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial

Presenter: Mohammed Ali

October 28, 2025

Presentation TCT 2025

TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

Presenter: Grant William Reed

October 27, 2025

Presentation TCT 2025

TCT 1261: Effect of PCSK9 Inhibitors on Coronary Plaque: A Meta-Analysis and Trial Sequential Analysis

Presenter: Paulo Roberto Tartuce Filho

October 27, 2025

Presentation TCT India 2025

Newer Lipid therapy Guidelines – Role of PCSK9 Inhibitors in ACS

Presenter: M. Srinivasa Rao

July 26, 2025

Presentation TCT 2024

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Presenter: Jonathan Los

October 27, 2024

Presentation TCT 2023

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

Presenter: Karol Watson

October 26, 2023

Presentation TCT 2023

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

Presenter: Sanjit Jolly

October 25, 2023

Presentation ACC 2023

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Presenter: Christie Ballantyne

March 05, 2023

Presentation TCT 2022

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Marc Bonaca

September 17, 2022

Presentation TCT 2021

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Connie Hess

November 06, 2021

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation JIM 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presenter: Giuseppe Musumeci

February 13, 2020

Presentation Cardiovascular Interventions 2019

PCSK9 Inhibitors for the Interventionalist: Which Patients Do We Choose and How Do We Use?

Presenter: Matthew J. Budoff

November 01, 2019

Presentation TCT 2019

Role of PCSK9 Inhibitors Post-PCI and ACS

Presenter: Marc Bonaca

September 26, 2019

Presentation Controversies and Advances 2018

Updateon PCS K-9 Inhibition

Presenter: P.K. Shah

November 15, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation Controversies and Advances 2017

PCSK9 Inhibitors - Are They Worth The Money?

Presenter: Michael J. Blaha

November 16, 2017

Presentation TCT 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presenter: Gregg W. Stone, Peter H. Stone, Evan A. Stein

November 01, 2017

Presentation CDM 2017

From Andreas Gruentzig to PCSK9: How Angioplasty Transformed Cardiovascular Care

Presenter: Spencer B. King

October 06, 2017

Presentation CDM 2017

Can Heart Disease be Eventually Abolished? The PCSK9 Revolution

Presenter: Robert A. Vogel

October 06, 2017

Advertisement

TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial

TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

TCT 1261: Effect of PCSK9 Inhibitors on Coronary Plaque: A Meta-Analysis and Trial Sequential Analysis

Newer Lipid therapy Guidelines – Role of PCSK9 Inhibitors in ACS

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Optimal LDL levels in patients with ACS undergoing PCI

PCSK9 Inhibitors for the Interventionalist: Which Patients Do We Choose and How Do We Use?

Role of PCSK9 Inhibitors Post-PCI and ACS

Updateon PCS K-9 Inhibition

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

PCSK9 Inhibitors - Are They Worth The Money?

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

From Andreas Gruentzig to PCSK9: How Angioplasty Transformed Cardiovascular Care

Can Heart Disease be Eventually Abolished? The PCSK9 Revolution

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content